One-year outcome following biological or mechanical valve
replacement for infective endocarditis

J 2015

One-year outcome following biological or mechanical valve replacement for infective endocarditis

DELAHAYE, F.; V.H. CHU; J. ALTCLAS; B. BARSIC; A. DELAHAYE et al.

Základní údaje

Originální název

One-year outcome following biological or mechanical valve replacement for infective endocarditis

Autoři

Vydání

International Journal of Cardiology, Clare (Ireland), Elsevier Ireland Ltd. 2015, 0167-5273

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 4.638

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14740/15:00082466

Organizační jednotka

Středoevropský technologický institut

Klíčová slova anglicky

Infective endocarditis; Surgery; Valve prosthesis

Štítky

rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 22. 3. 2016 11:11, Mgr. Eva Špillingová

Anotace

V originále

Background: Nearly half of patients require cardiac surgery during the acute phase of infective endocarditis (IE). We describe the characteristics of patients according to the type of valve replacement (mechanical or biological), and examine whether the type of prosthesis was associated with in-hospital and 1-year mortality. Methods and results: Among 5591 patients included in the International Collaboration on Endocarditis Prospective Cohort Study, 1467 patients with definite IE were operated on during the active phase and had a biological (37%) or mechanical (63%) valve replacement. Patients who received bioprostheses were older (62 vs 54 years), more often had a history of cancer (9% vs 6%), and had moderate or severe renal disease (9% vs 4%); proportion of health care-associated IE was higher (26% vs 17%); intracardiac abscesses were more frequent (30% vs 23%). In-hospital and 1-year death rates were higher in the bioprosthesis group, 20.5% vs 14.0% (p = 0.0009) and 25.3% vs 16.6% (p < .0001), respectively. In multivariable analysis, mechanical prostheses were less commonly implanted in older patients (odds ratio: 0.64 for every 10 years), and in patients with a history of cancer (0.72), but were more commonly implanted in mitral position (1.60). Bioprosthesis was independently associated with 1-year mortality (hazard ratio: 1.298). Conclusions: Patients with IE who receive a biological valve replacement have significant differences in clinical characteristics compared to patients who receive a mechanical prosthesis. Biological valve replacement is independently associated with a higher in-hospital and 1-year mortality, a result which is possibly related to patient characteristics rather than valve dysfunction. (C) 2014 Elsevier Ireland Ltd. All rights reserved.

Citovat

DELAHAYE, F.; V.H. CHU; J. ALTCLAS; B. BARSIC; A. DELAHAYE; Tomáš FREIBERGER; D.L. GORDON; M.M. HANNAN; B. HOEN; S.S. KANJ; T. LEJKO-ZUPANC; C.A. MESTRES; O. PACHIRAT; P. PAPPAS; C. LAMAS; C. SELTON-SUTY; R. TAN; P. TATTEVIN a A. WANG. One-year outcome following biological or mechanical valve replacement for infective endocarditis. International Journal of Cardiology. Clare (Ireland): Elsevier Ireland Ltd., 2015, roč. 178, January, s. 117-123. ISSN 0167-5273. Dostupné z: https://doi.org/10.1016/j.ijcard.2014.10.125.

@article{1228906,
   author = {Delahaye, F. and Chu, V.H. and Altclas, J. and Barsic, B. and Delahaye, A. and Freiberger, Tomáš and Gordon, D.L. and Hannan, M.M. and Hoen, B. and Kanj, S.S. and LejkoandZupanc, T. and Mestres, C.A. and Pachirat, O. and Pappas, P. and Lamas, C. and SeltonandSuty, C. and Tan, R. and Tattevin, P. and Wang, A.},
   article_location = {Clare (Ireland)},
   article_number = {January},
   doi = {https://doi.org/10.1016/j.ijcard.2014.10.125},
   keywords = {Infective endocarditis; Surgery; Valve prosthesis},
   language = {eng},
   issn = {0167-5273},
   journal = {International Journal of Cardiology},
   title = {One-year outcome following biological or mechanical valve replacement for infective endocarditis},
   url = {http://www.sciencedirect.com/science/article/pii/S0167527314020622#},
   volume = {178},
   year = {2015}
}

TY  - JOUR
ID  - 1228906
AU  - Delahaye, F. - Chu, V.H. - Altclas, J. - Barsic, B. - Delahaye, A. - Freiberger, Tomáš - Gordon, D.L. - Hannan, M.M. - Hoen, B. - Kanj, S.S. - Lejko-Zupanc, T. - Mestres, C.A. - Pachirat, O. - Pappas, P. - Lamas, C. - Selton-Suty, C. - Tan, R. - Tattevin, P. - Wang, A.
PY  - 2015
TI  - One-year outcome following biological or mechanical valve replacement for infective endocarditis
JF  - International Journal of Cardiology
VL  - 178
IS  - January
SP  - 117-123
EP  - 117-123
PB  - Elsevier Ireland Ltd.
SN  - 01675273
KW  - Infective endocarditis
KW  - Surgery
KW  - Valve prosthesis
UR  - http://www.sciencedirect.com/science/article/pii/S0167527314020622#
L2  - http://www.sciencedirect.com/science/article/pii/S0167527314020622#
N2  - Background: Nearly half of patients require cardiac surgery during the acute phase of infective endocarditis (IE). We describe the characteristics of patients according to the type of valve replacement (mechanical or biological), and examine whether the type of prosthesis was associated with in-hospital and 1-year mortality. Methods and results: Among 5591 patients included in the International Collaboration on Endocarditis Prospective Cohort Study, 1467 patients with definite IE were operated on during the active phase and had a biological (37%) or mechanical (63%) valve replacement. Patients who received bioprostheses were older (62 vs 54 years), more often had a history of cancer (9% vs 6%), and had moderate or severe renal disease (9% vs 4%); proportion of health care-associated IE was higher (26% vs 17%); intracardiac abscesses were more frequent (30% vs 23%). In-hospital and 1-year death rates were higher in the bioprosthesis group, 20.5% vs 14.0% (p = 0.0009) and 25.3% vs 16.6% (p < .0001), respectively. In multivariable analysis, mechanical prostheses were less commonly implanted in older patients (odds ratio: 0.64 for every 10 years), and in patients with a history of cancer (0.72), but were more commonly implanted in mitral position (1.60). Bioprosthesis was independently associated with 1-year mortality (hazard ratio: 1.298). Conclusions: Patients with IE who receive a biological valve replacement have significant differences in clinical characteristics compared to patients who receive a mechanical prosthesis. Biological valve replacement is independently associated with a higher in-hospital and 1-year mortality, a result which is possibly related to patient characteristics rather than valve dysfunction. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
ER  -

DELAHAYE, F.; V.H. CHU; J. ALTCLAS; B. BARSIC; A. DELAHAYE; Tomáš FREIBERGER; D.L. GORDON; M.M. HANNAN; B. HOEN; S.S. KANJ; T. LEJKO-ZUPANC; C.A. MESTRES; O. PACHIRAT; P. PAPPAS; C. LAMAS; C. SELTON-SUTY; R. TAN; P. TATTEVIN a A. WANG. One-year outcome following biological or mechanical valve replacement for infective endocarditis. \textit{International Journal of Cardiology}. Clare (Ireland): Elsevier Ireland Ltd., 2015, roč.~178, January, s.~117-123. ISSN~0167-5273. Dostupné z: https://doi.org/10.1016/j.ijcard.2014.10.125.

Přehled o publikaci